Pipeline

FASN Inhibitor

Indication

Preclinical

Phase 1

Phase 2

Phase 3

TVB-2640

NASH

Title

58%

TVB-2640

Oncology

Title

58%

TVB-3567

Undisclosed

Title

22%

FASN Inhibitor – TVB-2640

Indication – NASH

Phase 2

Title

70%

FASN Inhibitor – TVB-2640

Indication – Oncology

Phase 2

Title

70%

FASN Inhibitor – TVB-3567

Indication – Undisclosed

Preclinical

Title

30%

NASH Clinical Studies

Phase 1 in high BMI population completed – NCT02948569
Phase 2 in NASH patients ongoing – NCT03938246

Oncology Clinical Studies

Phase 1 solid tumor study completed – NCT02223247
Phase 1/2 Investigator or grant funded studies ongoing

  • Phase 1 in Colon cancer – NCT02980029
  • Phase 2 in Breast cancer – NCT03179904
  • Phase 2 in Astrocytoma – NCT03032484
  • Phase 2 in Non-small cell lung cancer, K-Ras mutant – NCT03808558

To learn more about clinical trials involving our product candidates, please visit ClinicalTrials.gov. ClinicalTrials.gov is a registry of publicly and privately supported clinical studies involving human participants conducted around the world. To find information on trials run by Sagimet/3-V Biosciences, our development partners, or by independent investigators, use the “Search for Studies” function and enter the product candidates name.

FASNHIV therapy-induced steatohepatitis Tamoxifen-induced steatohepatitisAnti-Viral (HCV, RSV, rhinovirus)Parkinsons DiseaseFibrotic diseasesAcneFASNAdditional Possible Disease Indications